Similar Papers

Paper Title
Journal
Date
Author
Immunophenotypically Aberrant Stem Cells in Myelodysplastic Syndromes: A Biomarker for Leukemic Progression
Margot F Van Spronsen ... Arjan A Van De Loosdrecht
Blood | VOL. 130
Margot F Van Spronsen, et. al.Margot F Van Spronsen ... Arjan A Van De Loosdrecht
25 Jun 2021
RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry
Deepak Singhal ... Devendra K Hiwase
Blood | VOL. 126
Deepak Singhal, et. al.Deepak Singhal ... Devendra K Hiwase
03 Dec 2015
Oxidative Stress in Stem / Progenitor Cells and Specific Antioxidant Response in Bone Marrow from Myelodysplastic Syndrome Patients
Frederic Picou ... Olivier Herault
Blood | VOL. 130
Frederic Picou, et. al.Frederic Picou ... Olivier Herault
25 Jun 2021
<p>Patients of Myelodysplastic Syndrome with Mild/Moderate Myelofibrosis and a Monosomal Karyotype are Independently Associated with an Adverse Prognosis: Long-Term Follow-Up Data</p>
Na Wang ... Hongzhi Xu
Cancer Management and Research | VOL. Volume 12
Na Wang, et. al.Na Wang ... Hongzhi Xu
01 Jul 2020
View more papers

More From: HemaSphere

Paper Title
Journal
Date
Author
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.
Christine E Ryan ... Matthew S Davids
HemaSphere | VOL. 9
Christine E Ryan, et. al.Christine E Ryan ... Matthew S Davids
01 Jan 2025
"Low-risk" myelodysplastic neoplasm (MDS): Time for a name change?
Shoshana Burke ... Stephen P Hibbs
HemaSphere | VOL. 9
Shoshana Burke, et. al.Shoshana Burke ... Stephen P Hibbs
01 Jan 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.
Maximilian Merz ... Nico Gagelmann
HemaSphere | VOL. 9
Maximilian Merz, et. al.Maximilian Merz ... Nico Gagelmann
01 Jan 2025
Issue Information
-
HemaSphere | VOL. 9
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.